MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.4 USD | +0.57% |
|
+2.82% | +18.74% |
Financials (USD)
| Sales 2024 * | 64.18B | Sales 2025 * | 68.68B | Capitalization | 326B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B | Net income 2025 * | 22.25B | EV / Sales 2024 * | 5.37 x |
| Net Debt 2024 * | 18.6B | Net Debt 2025 * | 7.28B | EV / Sales 2025 * | 4.85 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.4
x | Employees | 71,000 |
| Yield 2024 * |
2.4% | Yield 2025 * |
2.54% | Free-Float | 70.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | +0.57% | ||
| 1 week | +2.82% | ||
| Current month | +3.11% | ||
| 1 month | +1.47% | ||
| 3 months | +5.39% | ||
| 6 months | +21.86% | ||
| Current year | +18.74% |
1 week
122.70
129.94
1 month
122.70132.79
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 254 M€ | +13.39% | - | |
| 5.61% | 17 M€ | +7.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 129.4 | +0.57% | 5,009,433 |
| 24-06-04 | 128.7 | +0.23% | 6,440,167 |
| 24-06-03 | 128.4 | +2.29% | 7,702,676 |
| 24-05-31 | 125.5 | +0.81% | 18,150,452 |
| 24-05-30 | 124.5 | -1.09% | 13,003,476 |
Delayed Quote Nyse, June 05, 2024 at 04:00 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
128.7
USD
Average target price
142.7
USD
Spread / Average Target
+10.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.74% | 326B | |
| +42.69% | 750B | |
| +34.11% | 606B | |
| -6.87% | 356B | |
| +6.76% | 286B | |
| +18.08% | 246B | |
| -3.44% | 213B | |
| +11.35% | 213B | |
| +2.64% | 167B | |
| +6.72% | 165B |
- Stock Market
- Equities
- MRK Stock
